Aktis Oncology, Inc. AKTS · SEC Filings

website

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopha...

Price16.37

Market Cap879.83 M

Float486.23 K

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

News

TYPE

HEADLINE

FILED AT

8-K

Aktis Oncology Reports Second Quarter 2026 Financial Results and Clinical Pipeline Progress

Aug 13, 2026

8-K

Aktis Oncology Reports Q1 2026 Financial Results and Clinical Pipeline Progress

May 11, 2026

8-K

Aktis Oncology Appoints Industry R&D Veteran Glenn Gormley, MD, PhD to its Board of Directors

Apr 16, 2026

8-K

Aktis Oncology Announces FDA Clearance of IND Applications for AKY-2519 and Provides 2025 Financial Results

Mar 30, 2026

8-K

Aktis Oncology, Inc. Announces Amended and Restated Certificate of Incorporation and Bylaws

Jan 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

SHARE RESALE REGISTRATION | Shares amount: 17,650,000 | Share price: $18 | Offering amount: $317,700,000

Jan 9, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 12, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Jan 7, 2026

S-1/A

SHARE RESALE REGISTRATION | Shares amount: 11,775,000 | Share price: $17

Jan 7, 2026

S-1/A

SHARE RESALE REGISTRATION | Shares amount: 11,775,000 | Share price: $17

Jan 5, 2026

S-1

OFFERING | Bank: J.P. Morgan, BofA Securities, Leerink Partners, TD Cowen

Dec 19, 2025

DRS/A

Form DRS/A - Draft Registration Statement: [Amend]

Nov 14, 2025

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Czibere Akos (Reporting)

Sep 24, 2026

144

Form 144 - Report of proposed sale of securities

Sep 23, 2026

Herrmann Ken (Reporting)

Jul 21, 2026

Herrmann Ken (Reporting)

Jul 20, 2026

144

Form 144 - Report of proposed sale of securities

Jul 20, 2026

144

Form 144 - Report of proposed sale of securities

Jul 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 9, 2026

CORRESP

Form CORRESP - Correspondence

Jan 6, 2026

CORRESP

Form CORRESP - Correspondence

Jan 6, 2026

LETTER

Form UPLOAD - SEC-generated letter

Dec 5, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 7, 2024